Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Minority Interest (2019 - 2025)

aTYR PHARMA's Minority Interest history spans 7 years, with the latest figure at -$192000.0 for Q4 2025.

  • For Q4 2025, Minority Interest fell 2.67% year-over-year to -$192000.0; the TTM value through Dec 2025 reached -$192000.0, down 2.67%, while the annual FY2025 figure was -$192000.0, 2.67% down from the prior year.
  • Minority Interest reached -$192000.0 in Q4 2025 per ATYR's latest filing, down from -$191000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of -$170000.0 in Q1 2021 to a low of -$192000.0 in Q4 2025.
  • Average Minority Interest over 5 years is -$182100.0, with a median of -$184000.0 recorded in 2024.
  • Peak YoY movement for Minority Interest: decreased 6.13% in 2021, then increased 0.54% in 2024.
  • A 5-year view of Minority Interest shows it stood at -$175000.0 in 2021, then fell by 2.86% to -$180000.0 in 2022, then fell by 4.44% to -$188000.0 in 2023, then increased by 0.53% to -$187000.0 in 2024, then decreased by 2.67% to -$192000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Minority Interest are -$192000.0 (Q4 2025), -$191000.0 (Q3 2025), and -$189000.0 (Q2 2025).